CA-XPRIZE
XPRIZE , the world’s leader in designing and operating incentive competitions to solve humanity’s grand challenges, reveals the XPRIZE Pandemic Alliance, a global coalition that combines the power of collaboration, competition, shared innovation and radical thinking to accelerate solutions that can be applied to COVID-19 and future pandemics.
The XPRIZE Pandemic Alliance launched to address the immediate needs of the COVID-19 crisis by expanding visibility into solutions underway. This launch comes with an open call to arms to the world’s innovators, clinicians, researchers, data scientists, institutions, and experts to join the Alliance and share existing work and resources using covid19.xprize.org . This website will allow the global community to:
- Participate in the latest breakthroughs, research and solutions in development;
- Make asks of what they need and allow XPRIZE, the Alliance members and their vast network of supporters and partners to offer their resources to help enable and accelerate innovators to reach their goals faster.
In the immediate term, the Alliance will focus on areas such as accelerating solutions for remote care, provisioning personal protective equipment to the front lines, increasing access to testing, and improving food and medicine security for vulnerable populations, among others.
As part of this Alliance, researchers and scientists are invited to share and access data through the XPRIZE Data Collaborative, a unique platform for researchers and innovators to collaborate, share and learn from data in a broad spectrum of fields in their search for solutions. This trove of data aims to unlock new approaches to fighting pandemics and will serve as the backbone to the collective effort that will prepare us for additional pandemic spikes like COVID-19, or other viral threats.
As part of the XPRIZE Data Collaborative, our launch partner, Anthem, is taking the lead by providing vetted partners with access to one of the largest certified deidentified data set including years of longitudinal data for prior viral outbreaks (e.g., swine flu, avian flu, influenza).
XPRIZE will also host and launch a series of rapid data challenges in support of the Alliance’s initiatives, which may include developing an early warning system for future pandemics, predictive models for public health resource allocation, more efficient and affordable diagnostics, treatments and cures that can be rapidly reproduced, or others based on insights drawn from the collaborators.
Other notable global partners that have already agreed to join the Alliance include United States Department of Veterans Affairs, Ending Pandemics, Intel, Illumina, IEEE Standards Association, MIT Solve, C2 International, Cloudbreak Health, the Foundation Botnar, McGill University, Nvidia, the Patrick J. McGovern Foundation, PPE Coalition, and UCSD. XPRIZE is actively calling for more partners and members to join the Alliance.
“There are few times in recent history when one pandemic has affected so many people, but with all of us focused on one problem, it means impact and solutions will only be accelerated, and we’re excited to work with Anthem to amplify the potential of this platform in quickly enabling global talent to join the fight,” said XPRIZE CEO Anousheh Ansari . “At XPRIZE, we believe radical breakthroughs can come from anyone, anywhere, and our response to COVID-19 will help provide solutions when humanity’s most vulnerable need it most.”
“In this time of crisis, we see an opportunity to come together as a community via the powerful XPRIZE platform to address the most acute needs in the system today and to accelerate new solutions: from protecting our healthcare workers at the front lines and proactively taking care of the high risk populations to developing new approaches to diagnostics, therapy and vaccines,” said Rajeev Ronanki, Chief Digital Officer at Anthem.
“COVID-19 is not the first, nor the last pandemic humanity will face, and future pandemics could be far worse,” said XPRIZE Founder and Executive Chairman Peter H. Diamandis , MD. “For 25 years, XPRIZE has focused on solving global grand challenges, crowdsourcing solutions. The XPRIZE does this by inspiring innovators around the world to use exponential technologies to address problems in unbelievably short timeframes. The XPRIZE Pandemic Alliance will leverage data and human collaboration like never before to facilitate technological breakthroughs for the benefit of humankind.”
For more information, visit covid19.xprize.org .
Additional Quotes from XPRIZE Pandemic Alliance Partners:
“Technology can play a role in helping us to address the world’s largest challenges,” said Stacey Shulman, Chief Innovation Officer and VP, IOT Group, Intel. “Intel is partnering with XPRIZE to enable the larger community to find creative and impactful solutions for this global pandemic.”
“Never before have we had both the technology and collective will to develop a proactive global network for real time assessment and monitoring of infectious epidemics,” said Dr. Phil Febbo, Senior Vice President and Chief Medical Officer, Illumina. “We are pleased to be participating and helping to ensure that laboratories using our sequencers worldwide can integrate into a global community committed to preventing pandemics.”
“In response to the ongoing threat of COVID-19, Solve is focused on finding and supporting innovative solutions that address global health preparedness, early detection, and rapid response,” said Alex Amouyel, Executive Director at MIT Solve. “Better data sharing and analysis is one area that is critical in the effort to slow and track the spread of COVID-19 and future disease outbreaks—and Solve is pleased to join the XPRIZE Global Pandemic Data Alliance in that endeavor.”
"We are finding solutions and new innovations guided by lived experience, empathy, and a love of humanity and coming from unexpected and underexplored sources—makers/tinkerers who are also frontline health workers, student inventors, data scientists driven by social purpose," said Vilas Dhar, Trustee of the Patrick J. McGovern Foundation. "This Alliance creates a platform to engage those actors and many more in a shared quest to alleviate suffering and create a new paradigm for pandemic response."
XPRIZE
XPRIZE designs and operates multi-million-dollar, global competitions to accelerate the development of technological breakthroughs that benefit humanity. Active competitions include the $10 Million ANA Avatar XPRIZE and the $5 Million IBM Watson AI XPRIZE, the $20 Million NRG COSIA Carbon XPRIZE, and the $10 Million Rainforest XPRIZE. For more information, visit xprize.org .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200326005217/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Quectel Launches RG660QA and RG660QB 5G Modules With Advanced Performance Features7.1.2026 18:00:00 CET | Press release
Quectel Wireless Solutions, an end-to-end global IoT solutions provider, today announces the launch of the RG600QA and RG660QB 5G module, based on the Qualcomm® X85 and X82 5G Modem-RF Systems. The RG660QA is based on X85 while the RG660QB is based onX82. Engineering samples of two first SKUs in the RG660Qx series have been already made available to customers and pre-production samples will be available to the market in Q2 2026. Designed for versatility, this module series supports a broad array of next generation 5G use cases, from home and business wireless broadband to mobile video, camera applications, and high-performance mobile hotspots. In indoor 5G CPE, it unlocks premium performance by enabling Wi-Fi 7 across the 2.4 GHz, 5 GHz, and 6 GHz bands, with integrated Bluetooth to support a full ecosystem of connected devices. With Ethernet speeds reaching up to 10 Gbps, the RG660Qx delivers the high-capacity backbone needed to power ultra-fast, reliable home and enterprise networks.
Sodali & Co Announces Executive Leadership Appointments7.1.2026 17:00:00 CET | Press release
Accelerates Firm Strategy to Deliver Global Integrated Stakeholder Solutions Sodali & Co (the ‘firm’ or ‘Sodali’), the leading global capital markets-centric stakeholder advisory firm, is pleased to announce four appointments to its Executive Leadership Team (ELT) under Chief Executive Officer Andrew Benett. These newly created senior roles will strengthen Sodali’s ability to respond to clients’ evolving needs with an integrated suite of shareholder, sustainability, and strategic communications advisory services delivered on a global scale. The appointments are as follows: Brett Clegg has been promoted to Chief Commercial Officer. Brett was previously Chairman of Sodali’s APAC region, based in the firm’s Sydney office. He specializes in advising clients on strategic communications, issues management, and capital markets transactions. Prior to Sodali, Brett spent over two decades in senior executive and editorial roles at some of Australia’s leading news brands, including The Australian
1NCE Continues Growth and Expands Its Software, AI and Services Offering7.1.2026 14:15:00 CET | Press release
In 2025 1NCE added another 10 million endpoints to its foundational IoT platform; now manages 40+ million intelligent products for 30,000 customers in 17 industries. Introduces new software, 1NCE Insights, the AI + IoT fusion of intelligence from its network that gives analytics and benchmark data on how customers can better setup, manage and optimize their device estates. 1NCE, a company offering a plug-and-play platform for creating and managing the world’s best IoT products, reports another strong growth year, adding another 10 million endpoints. The company now manages 40+ million intelligent products for 30,000+ customers across 17 industries. 1NCE’s software and connectivity platform has become a new industry standard, delivering hassle-free IoT in 170+ countries and regions. The company has a unique vantage point in the IoT ecosystem, with four billion data records per day collected through 250+ streams on the world’s largest IoT network in the cloud. The company launched a new
Prudentia Sciences Announces Series A Led by McKesson Ventures, Accelerating Due Diligence for Life Sciences Dealmaking7.1.2026 14:00:00 CET | Press release
Prudentia Sciences, a pioneer in AI-native due diligence for life sciences dealmaking, today announced that it has secured $20 million in Series A financing. The round was led by McKesson Ventures with participation from SignalFire. Existing investors include Iaso Ventures, Virtue and GV. This brings the company’s total funding to $27 million, following a $7 million seed round in 2024. Prudentia Sciences provides an AI-native platform that enables pharma companies, biotechs, and financial institutions to evaluate breakthrough medicines with unprecedented speed and rigor. By synthesizing complex clinical signals into actionable insights, Prudentia accelerates deal throughput and provides strategic leverage for acquisition, licensing, or investment decisions made by business development, investment, and diligence teams. The company’s human-in-the-loop approach orchestrates seamless collaboration between buyers, sellers, and intermediaries. This ensures a secure, compliant infrastructure
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 12:30:00 CET | Press release
FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trialCompass continues to advance commercial preparations to be launch-ready by the end of the year for COMP360 for treatment-resistant depression (TRD)Management will host webinar with KOL and industry leaders to discuss PTSD clinical trial and commercial preparations for TRD from 10:00-11:30 am ET on January 7th Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations f
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
